c-Myc Peptide is a useful displacement of c-Myc-tagged fusion proteins bound to anti-c-Myc antibodies in immunoassays. The successful inhibition of antibody binding by c-Myc peptide demonstrates binding is specific. c-Myc peptide participates in regulation of growth-related gene transcription.

The c-Myc Peptide is a synthetic peptide with an amino acid sequence that corresponds to the amino acids 410-419 of the C-terminal of human c-myc. Myc (c-Myc) is a regulator gene that codes for a transcription factor. c-Myc activation results in numerous biological effects. The first to be discovered was its capability to drive cell proliferation (upregulates cyclins, downregulates p21), but it also plays a very important role in regulating cell growth (upregulates ribosomal RNA and proteins), apoptosis (downregulates Bcl-2), differentiation and stem cell self-renewal. C-Myc is a very strong proto-oncogene and it is very often found to be upregulated in many types of cancers. c-Myc overexpression stimulates gene amplification, [1] presumably through DNA over-replication.

References: 1. Denis N, Kitzis A, Kruh J, Dautry F, Corcos D (August 1991). "Stimulation of methotrexate resistance and dihydrofolate reductase gene amplification by c-myc". Oncogene 6 (8): 1453–7.